Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry
- 1 January 2001
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 144 (1) , 111-117
- https://doi.org/10.1046/j.1365-2133.2001.03961.x
Abstract
Local injections of botulinum toxin type A (BTX-A) have been used successfully to treat focal hyperhidrosis, but because experimental data were lacking, doses have been chosen arbitrarily or empirically. To analyse dose dependency and duration of BTX-A-derived suppression of sweat gland activity. Employing a standardized scheme (four injections, square 2 x 2 cm), different doses of BTX-A [Dysport(R); 2.5-120 mouse units (MU)] were injected subcutaneously at the lateral aspects of both of the lower legs in 15 healthy volunteers. Sweat tests were performed before, and 3 weeks and 6 months after, BTX-A injections. Sweating was visualized by staining with iodine starch, and quantified by capacitance hygrometry after carbachol iontophoresis, the quantitative sudomotor axon reflex test (QSART). Iodine starch staining indicated a threshold dose of 10 MU (2.5 MU cm-2) leading to visible anhidrotic skin spots after 3 weeks in all subjects. This was maintained for 6 months with doses of 50 MU (12.5 MU cm-2) or higher, but the size of the anhidrotic skin area decreased over time (P < 0.001) indicating partial recovery at the edges. After 3 weeks QSART was significantly reduced (P < 0.02) and completely suppressed by doses of 80 MU (20 MU cm-2) or more, although after 6 months QSART increased again to pre-BTX-A levels (P < 0.001). Both methods indicated that the suppression of sweating is dose dependent (QSART: r = -0.70, P < 0.001; iodine starch staining: r = 0.74, P < 0.001). Our findings suggest that BTX-A effectiveness can be quantified by testing sudomotor function. For the first time threshold doses for the suppression of sweating have been defined.Keywords
This publication has 26 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosisBritish Journal of Dermatology, 1999
- Letters to the EditorMovement Disorders, 1998
- What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using DysportJournal of Neurology, Neurosurgery & Psychiatry, 1998
- The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type AMovement Disorders, 1997
- Botulinum toxin-a possible new treatment for axillary hyperhidrosisClinical and Experimental Dermatology, 1996
- Botulinum toxin: Influence on respiratory heart rate variationMovement Disorders, 1995
- Comparison of directly stimulated with axon‐reflex–mediated sudomotor responses in human subjects and in patients with diabetesMuscle & Nerve, 1993
- Quantitative assessment of sudomotor activity by capacitance hygrometryClinical Autonomic Research, 1993
- Therapeutic Uses of Botulinum ToxinNew England Journal of Medicine, 1991
- Quantitative sudomotor axon reflex test in normal and neuropathic subjectsAnnals of Neurology, 1983